Biomea Fusion (BMEA) announced its presentations at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management in Singapore, 18-20 November. Biomea will showcase three oral ...

GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, MarketBeat Ratings reports.

On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...